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CD5-negative chronic B cell lymphoproliferative disorders in leukemic phase (B-CLPD) are heterogeneous
and relatively uncommon pathologies that often lack a histopathological deﬁnition because of the absence
of accessible pathological tissue. We describe the clinical features and evolution-related variables of 156
patients with CD5/CD10-negative B-CLPD (median age 66 years, range 25–86). The median follow-up was 51
months (range 6–216), and overall 3- and 5-year survival was respectively 87 and 76%; 50 patients needed
therapy at diagnosis, 56 during follow-up, and 50 remained untreated until the last control. A combined clin-
ical, histological, cytomorphological, immunophenotypical, and cytogenetic diagnostic approach allowed
the complete classiﬁcation of only a minority of patients as being affected by splenic marginal zone or lym-
phoplasmacytic lymphoma; the majority of cases remained unclassiﬁable. Multivariate analysis showed that
the clinicohematological variables adversely related to overall survival were serum LDH levels and age,
whereas high serum LDH levels, hemoglobin levels of <11 g/dl, and splenomegaly related to treatment-free
time (in ‘‘wait and see’’ cases); only splenomegaly related to time to progression (in treated patients). In
conclusion, our retrospective study describes the clinical features and variables related to evolution in a
large group of patients with CD5/CD10-negative chronic B-cell lymphoid leukemias and underlines the fact
that a probable lymphoplasmacytic or marginal zone normal cell origin can be supposed in such leukemic
forms, but never surely demonstrated. Am. J. Hematol. 83:349–354, 2008. VC 2008 Wiley-Liss, Inc.
Introduction
Chronic B cell lymphoproliferative disorders in leukemic
phase (B-CLPD) are a frequent and biologically heteroge-
neous group of neoplastic disorders characterized by differ-
ent clinical behaviors and therapeutic responses, whose
ﬁrst-line deﬁnition is based on cell morphology, immuno-
phenotype ﬁndings, and clinical presentation [1]. Histopath-
ological analysis is very helpful for attributing the leukemic
picture to a speciﬁc clinicopathologic entity according to the
REAL/WHO classiﬁcation [2], but is not always available
because of the absence of easily accessible pathological
tissue, except for bone marrow whose examination is not
always sufﬁcient for a precise diagnostic deﬁnition.
Finally, as the development of cytogenetic and molecular
studies has allowed the identiﬁcation of speciﬁc markers for
only some subsets of these disorders, more speciﬁc diagnos-
tic evaluations are left to ﬂow cytometry analysis. Among the
different surface antigens, CD5 can be considered a quite reli-
able marker for classifying B-CLPD into two main groups:
CD5-positive forms, which are mainly represented by classi-
cal and atypical B-cell chronic lymphocytic leukemias (CLL),
mantle cell lymphomas (MCL) in leukemic phase, and rare
cases of splenic marginal zone lymphomas (SMZL), and CD5
negative cases, which mainly consist of non-Hodgkin lym-
phoma (NHL) in leukemic form as recently described by Ugo
et al. [3], particularly lymphoplasmacytic lymphoma (LPL) in
leukemic phase, SMZL with (>10%) or without villous lympho-
cytes, and hairy cell leukemia (HCL) and, less frequently,
other NHLs such as follicular lymphoma (FL).
HCL has a particular morphological and immunopheno-
typical presentation, and the leukemic phase of FL and
LCL is scarcely frequent, and there are also speciﬁc
markers (e.g., the expression of CD10 and the presence of
t(14;18) in FL), but it is not always possible to deﬁne the
diagnosis of the other CD5-negative forms. Consequently,
the aim of this study was to improve our knowledge of the
clinical features of this latter subset by retrospectively ana-
lyzing a broader series of cases referred to various Italian
Hematological Institutes. In addition to evaluating their main
clinical features, we also tried to identify the variables at
diagnosis that may relate to overall and failure free-survival.
Results
Cytomorphology analysis
In terms of morphology, 42/156 (27%) patients had typi-
cal CLL or CLL-like disease, 19 (12%) LPL in leukemic
phase, 30 (19%) SMZL without villous lymphocytes, and 15
(9.6%) SMZL with villous lymphocytes, 19 (12.1%) CLL/
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chronic prolymphocytic leukemia and 65 (42%) heterogene-
ous (polymorphic) forms.
Cytogenetic features
Conventional cytogenetic studies were available for 92 of
the156 patients, 44 (47.8%) of whom had a normal karyo-
type. Deletions (11q) or (13q) were found in 2 patients
each. Trisomy 12, 13, and 118 were detected in respec-
tive 8, 9, and 11 patients, and were more frequently associ-
ated with other cytogenetic abnormalities. The involvement
of chromosome 17 was detected in eight cases, and a
complex karyotype in 20 cases.
Clinicohematological features
The main clinicohematological features at diagnosis are
shown in Table I. The majority of patients had a quite good
performance status and 20 (12.8%) had B symptoms, 37
patients (23.7%) were anemic (Hb <11 g/dl), 46 (29.3%)
had increased LDH levels, and 53 out of 79 analyzed cases
(67.1%) had increased serum b2-microglobulin levels. Se-
rum monoclonal gammopathy was present at diagnosis in
42 patients (26.9%; IgM class in 28/42). Lymph node
involvement was absent or minimal (<3 sites and not con-
spicuous) in 127 patients (81.4%), but 29 (18.6%) had 3
lymph node sites, mainly with deep involvement; spleno-
megaly was present in110 patients (70.5%).
In all of the cases, bone marrow histology showed lym-
phoproliferative disorders sustained by mature B cell/lym-
phocytes: the inﬁltration pattern (described in 119 cases,
76.3%) was interstitial in 20 patients (16.8%), mixed in 69
(58%, with an intrasinusoidal component in nine cases),
nodular in 11 (9.2%), and diffuse in 19 (16%). Eight
patients underwent tissue biopsy during follow-up, leading
to histological diagnoses of marginal zone NHL in four
patients (one nodal and three splenic subtypes), small lym-
phocytic lymphoma in two, and LPL in two.
Diagnostic deﬁnition
On the basis of their clinical presentation, peripheral
blood cytomorphology and karyotype, bone marrow histo-
pathology, and the presence or absence of serum MC, a
possible diagnosis of SMZL or LPL could be postulated in
a number of cases. Thirty of the 156 patients (19.2%) could
reasonably be considered as having SMZL because they
had splenomegaly plus a compatible karyotype or cytomor-
phology or an intrasinusoidal bone marrow pattern; further-
more, 42/156 (27%) had a monoclonal component, 19 of
whom could be considered LPL because of the presence
of a serum monoclonal component and clear lymphoplas-
macytic leukemic cell differentiation. In the remaining 107
cases (unclassiﬁable group), no precise diagnostic deﬁni-
tion was possible retrospectively.
Survival analysis
As shown in Table I, there were statistically signiﬁcant
differences in a number of clinical variables between the
patients who were treated or not at diagnosis. Overall sur-
vival (OS) after 3 and 5 years was respectively 87 and 76%
(see Fig. 1). Fifty-six of the 106 initially untreated patients
required therapy after a median time freedom to treatment
(TFTT) of 55 months, and 24/50 initially treated patients
showed relapse/progression after a median time to progres-
sion (TTP) of 31 months (see Fig. 2). The clinical and hem-
atological features of the whole group at diagnosis were
evaluated in terms of their prognostic relevance for OS,
TFTT, and TTP by means of univariate and multivariate
analyses.
At univariate analysis (Table II), age, high serum LDH
levels, hemoglobin levels of <11 g/dl, low serum albumin,
and high b2-microglobulin levels, splenomegaly and treat-
ment at diagnosis signiﬁcantly correlated with OS, and high
serum LDH levels, hemoglobin levels of <11 g/dl, spleno-
megaly, lymphocytosis (>15 3 109/l), and performance sta-
TABLE I. Clinical and Hematological Characteristics of the Study Population
Variable
N (%)
Total cases
N 5 156 ‘‘W&W’’ N 5 106
Treatment at
diagnosis N 5 50 P value
M/F 85/71 (54/46) 58/48 (55/45) 27/23 (54/46) >0.50
Median age (years; range) 66 (25–87) 66 (25–84) 68 (45–87) 0.151
B symptoms 20 (12.8) 9 (8.5) 11 (22.0) 0.037
Performance status (ECOG):  2 23 (14.7) 13 (12.3) 7 (14.0) >0.5
Splenomegaly 110 (70.5) 63 (59) 47 (94) 0.005
Nodal disease 29 (18.6) 12 (11.3) 17 (34.0) 0.002
N. extranodal sites > 2 6 (3.8) 2 (1.9) 4 (8.0) 0.084
Bulky disease 20 (12.8) 9 (8.5) 11 (22.0) 0.037
Hb < 11 g/dl 37 (23.7) 18 (17.0) 19 (38.0) 0.008
Lymphocytes > 10 3 109/l 85 (54.5) 50 (47.2) 35 (70.0) 0.010
PLT < 100 3 109/l 14 (9.0) 7 (6.6) 7 (14.0) 0.144
Serum LDH value upper normal 46 (29.3) 23 (21.4) 23 (46.0) 0.003
ESR > 30 mm/h 53 (33.9) 35 (32.5) 18 (36.8) >0.50
b2-microglobulin > 2.6 mcg/ml* 53 (67.1) 33 (58.9) 20 (87.0) 0.018
Albumina > 3.5 g/dl 140 (89.8) 101 (95.3) 39 (78.0) 0.003
Bone marrow inﬁltration pattern*:
Interstitial 20 (16.8) 18 (23.0) 2 (4.9) 0.017
Nodular 11 (9.2) 4 (5.1) 7 (17.1)
Mixed 69 (58.0) 43 (55.1) 26 (63.4)
Diffuse 19 (16.0) 13 (16.7) 6 (14.6)
Serum monoclonal component 42 (26.9) 28 (26.4) 14 (28.0) >0.50
HCV antibodies* 6 (5.3) 3 (3.7) 3 (9.7) 0.343
*Not available for assessment: 77 cases for B2M, 37 for inﬁltration pattern and 43 for HCV antibodies.
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tus >1 signiﬁcantly corrrelated with TFTT. Only splenomeg-
aly correlated with TTP.
At multivariate analysis (Table III), only serum LDH levels
and an age of >60 years retained their prognostic rele-
vance for OS (hazard ratios [HR] 3.00 and 6.82, respec-
tively), but the factor ‘‘no treatment at diagnosis’’ (HR 2.32,
P 5 0.008 at univariate analysis) did not (P 5 0.244). In
relation to TFTT, serum LDH, hemoglobin and splenomeg-
aly (HRs 4.21, 3.66, and 2.27 respectively) retained their
prognostic relevance.
We subsequently constructed a simple prognostic scor-
ing system for OS by assigning 1 point to an age of >60
years and 1 point to high LDH levels (class I, low risk,
score 0; class II, intermediate risk, score 1; class III, high
risk, score 2) (Table IV). Our scoring system identiﬁed three
subsets of patients characterized by different clinical out-
comes (Fig. 3).
Finally, on the basis of our diagnostic hypotheses, we
statistically analyzed dividing our patients into three sub-
groups: there were no signiﬁcant differences in terms of
clinical presentation, OS, TTP, or TFTT between the MZL
(30 patients), LPL (19), and unclassiﬁable group (107), but
there was a slight prevalence of splenomegaly in MZL; at
the time of the analysis, median OS in the three groups
was respectively 119, 170, and 122 months (P > 0.50)
(data not shown).
Discussion
B-CLPDs are a heterogeneous group of neoplastic disor-
ders whose appropriate diagnostic deﬁnition comes from
the concurrence of clinical, cytomorphological, histological,
cytoﬂuorimetric, cytogenetic, and molecular ﬁndings; how-
ever, as a histopathological analysis is not available in
many cases because of the absence of a suitable bioptic
approach, the diagnosis is often left to a immunocytomor-
phological evaluation of leukemic cells in addition to bone
marrow histology.
A simple and routinely used marker such as CD5 is often
capable of separating B-CLPD cases into two main groups
on the basis of its functional and anatomic distribution. The
CD5-positive group mainly includes classical and atypical
B-CLL and MCL in leukemic phase, although rare cases of
MZL and LPL have also been reported [3,4]; in this sense,
an RMH score of 4–5 or less helps in the correct deﬁnition
of typical B-CLL versus other pathological situations [5,6].
The group of CD5-negative disorders include heterogene-
ous entities such as prolymphocytic leukemia, HCL, FL,
SMZL, LPL in leukemic phase, and rare cases of LCL [2,5–
7]. HCL, FL, and LCL are often easily diagnosed on the ba-
sis of their cytomorphology, bone marrow histology, immu-
nophenotype features, and/or speciﬁc genetic markers, and
in some of the other cases, a deﬁnite WHO diagnosis may
be made if lymph node or splenic tissue is examined (as
they are easily recognized, these lymphoid neoplasias are
often included in speciﬁc clinical trials) [3,4].Figure 1. OS of the study population (156 cases).
Figure 2. TFTT (A) 106 ‘‘W&W’’ patients and TTP (B) 50 upfront treated patients.
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The remaining forms of CD5-negative B-CLPD are char-
acterized by atypical and various morphological features,
undistinctive immunophenotype patterns, and the absence
of any pathognomonic molecular markers [8–13]. The pos-
sibility of performing a lymphoid tissue biopsy has allowed
some of these CD5-negative B-CLPDs to be classiﬁed
within WHO-deﬁned nosological entities, such as variants
of FL and nodal or splenic MZL or LPL. In the absence
of a histological deﬁnition, these forms are frequently
excluded from clinical trials, and our knowledge of their clin-
ical characteristics and outcomes is limited. In comparison
with B-CLL, it seems that they are characterized by similar
survival rates, more frequent splenic involvement, and sys-
temic symptoms; it is less clear whether or not their clinical
presentation is more advanced at diagnosis [7,9,10,14–16].
We systematically analyzed a large series of patients in
an attempt to contribute towards better deﬁning CD5-nega-
tive B-CLPDs, but as described above, a probable diagno-
sis at clinical presentation was possible in only 49 patients.
As underlined by other authors [3], morphological aspect
alone was inadequate distinguishing CLL from the other B-
CLPDs as 42 patients (27%) had a CLL/CLL-like morphol-
ogy despite an RMH score of 3. The cytogenetic analysis
showed a normal karyotype in many patients, and the
documented chromosomal abnormalities were not useful
for better deﬁning this subgroup, with the exception of
some cases in which the presence of 13 or 118 sug-
gested a diagnosis of marginal zone cell lymphoma. Bone
marrow histology patterns were available for 119 patients,
but only nine had a diagnostic ‘‘intrasinusoidal pattern’’ and
only 10 showed lymplasmacytic differentiation.
When a diagnosis could be made on the basis of this
multiparametric diagnostic approach, it was hypothesized
that these leukemic forms had a lymphoplasmacitic or mar-
ginal zone normal origin.
As in the case of all low-grade lymphoproliferative disor-
ders, our patients experienced an indolent phase during
which no treatment was required: only 50 of the 156
patients started treatment at the time of diagnosis, mainly
because of the presence of B symptoms and/or bulky dis-
ease and/or anemia; the remaining 106 remained untreated
for a median of 33 months.
Multivariate analysis showed that the relationships
between OS and LDH levels and age were statistically sig-
niﬁcant. We compared our cases with mortality due to any
cause in the Italian population (‘‘La mortalita` per causa in
Italia 1980–1994’’, Istituto Superiore Italiano di Sanita`;
ICD9-CM http://www.mortalita.iss.it), and found that age
remained statistically signiﬁcant, especially in patients aged
70–80 years: older than that, age tended to become less
predictive, but this may have been due to the small sample
size (data not shown). On the basis of these two simple
variables, we could identify three patient categories charac-
terized by a different prognosis.
Finally, serum LDH levels, hemoglobin levels, and
splenomegaly could be considered variables related to the
need for treatment in a patient affected by CD5/CD10-neg-
ative B-CLPD following a ‘‘wait and see’’ regimen.
In conclusion, we believe that CD5/CD10-negative B-
CLPDs are a heterogeneous group of conditions in which it
is frequently complex to recognize a neoplastic cell origin,
especially for institutions that cannot apply advanced immu-
TABLE II. Clinical Parameters Inﬂuencing Overall Survival (OS),
Time Freedom To Treatment (TFTT) and Time To Progression
(TTP) at Univariate Analysis
Variable
P-value
OS TFTT TTP
No of patients 156 106 50
Age > 60 years <0.001 >0.50 >0.50
Age std form (mean 66 yrs, SD 10) 0.001 >0.50 >0.50
LDH ratio > normal <0.001 <0.001 0.285
Haemoglobin < 11 g/dl 0.015 <0.001 >0.50
Serum albumin < 3.5 g/dl 0.021 >0.5 0.400
b2-microglobulin ratio > normal 0.028 0.127 0.382
Splenomegaly 0.050 0.010 >0.50
Bulky disease 0.073 0.170 >0.50
Lymphocytosis > 15 3 103 ll21 0.086 0.039 0.218
B symptoms 0.087 0.061 >0.50
Bone marrow inﬁltration (%) 0.094 0.190 >0.5
ESR > 30 mm/h 0.463 0.167 >0.50
Sex F >0.50 0.237 0.182
PS 2–3 >0.50 0.013 >0.5
No treatment at diagnosis 0.008 – –
TABLE III. Clinical Parameters Inﬂuencing Overall Survival (OS)
and Time Freedom to Therapy (TFTT) at Multivariate Analysis
Variable Coeff. (SE) HR (CI 95%) P value
OS
Age > 60 yrs 1.92 (0.60) 6.82 (2.08–22.3) 0.001
LDH ratio > normal 1.10 (0.33) 3.00 (1.56–5.76) 0.001
TFTT
LDH ratio > normal 1.44 (0.33) 4.21 (2.20–8.07) <0.001
Hb < 11 g/dl 1.30 (0.37) 3.66 (1.78–7.51) <0.001
Splenomegaly 0.820 (0.313) 2.27 (1.23–4.20) 0.009
TABLE IV. Prognostic Scoring System for Overall Survival Based
on Age > 60 Years and/or LDH Ratio > Normal
Score risk N (%) Median (months) P value
OS
Low – Score 0 35 (22) –
Intermediate – Score 1 89 (50) 91 I vs. L <0.001
High – Score 2 33 (21) 59 H vs. I 0.006
Total 156
Figure 3. OS stratiﬁed by proposed prognostic score (age > 60 year and/or LDH
ratio > normal).
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nophenotypical and molecular methods. Like other authors,
we believe that a large proportion of these forms represent
the leukemic presentation of lymphoproliferative disorders
classiﬁable in the WHO categories of marginal zone or
LPLs, although only a minority of cases can be diagnosed
certainly at the time of clinical presentation. Our prognostic
features may be useful for evaluating the need for treat-
ment and predicting the tendency to treatment failure in
individual patients.
Materials and Methods
Patients
The study involved 156 patients with newly diagnosed CD5-negative
B-CLPD (male/female ratio 5 85/71; median age at diagnosis 66 years,
range 25–87), who were referred to 10 Italian Institutions between
1990 and 2003. Five of the institutions belonged to the ‘‘Gruppo Italiano
Studio Linfomi’’ (GISL: 66 patients) and four to the ‘‘Gruppo Multiregio-
nale’’ (45 patients); the 10th was the Division of Hematology, Ospedale
Maggiore, Bergamo, Italy (45 patients). The data were managed and
analyzed in accordance with the ethical rules of the Modena Cancer
Registry and the Helsinki Declaration of 1964 (as revised in 2000). All
of the cases had light chain restricted, CD19-positive and CD5-negative
lymphocytosis (5 3 109/l) diagnosed on the basis of conventional pro-
cedures, including the usual laboratory tests (serum LDH, b2 microglo-
bulin, HCV-Ab status, liver, and kidney function). All of the patients
underwent bone marrow aspiration and a trephine biopsy at diagnosis
and whenever considered necessary during follow-up. CD10-positive
leukemic follicular lymphomas (FLs), HCL and large B-cell lymphomas
in leukemic phase were excluded.
A preliminary database of 172 patients was established, from which
16 cases were excluded because they did not respect the inclusion cri-
teria or their clinical data were incomplete; 24 of the included patients
have been described in a previously published study [17]. At the time
of analysis, the median follow-up was 51 months (range 6–216), which
was not signiﬁcantly different from that of the patients who were still
alive (55 months, range 6–216). Thirty-eight patients had died: 23
(60.5%) because of disease progression, four (10.5%) because of
treatment toxicity, and 11 (29%) for other reasons.
Treatment
A ‘‘watch and wait’’ policy was adopted at diagnosis in the case of
106 patients (67.9%), the remaining 50 (32.1%) received chemother-
apy. Fifty-six of the patients in the ‘‘watch and wait’’ group started ther-
apy during follow-up (median time to treatment 19 months, range 3–
117), giving a total of 106 treated patients.
Although this was a retrospective study, the study centers had a
common policy concerning the need for treatment (due their well-estab-
lished cooperation in clinical trials), which was considered appropriate
if there was at least one of the following active disease criteria: sys-
temic symptoms, bulky disease, progressive marrow failure with the de-
velopment or worsening of anemia (Hb < 2 g/dl below the lower normal
limit or < 10 g/dl), and/or thrombocytopenia < 100 3 109/l, a lympho-
cyte doubling time of <12 months, progressive splenomegaly, and/or
lymph adenopathy.
The ﬁrst-line treatments included monochemotherapy (alkylating
agents) in 55 cases (51.8%), polychemotherapy with anthracyclines in
21 (19.9%), polychemotherapy without anthracyclines in four (3.8%),
and purine analogues in 26 (24.5%). Purine analogues were prevalently
used for the patients treated after an indolent phase because they
started therapy more recently. Responses were evaluated on the basis
of the guidelines proposed by the International Workshop and the
Working Group for Chronic Lymphocytic Leukemia [18,19].
Cytomorphological analysis
Peripheral blood ﬁlms stained with May-Grunwald–Giemsa were mor-
phologically evaluated using the FAB criteria (1) and the WHO’s revised
REAL classiﬁcation (2), and the cases were grouped on the basis of
morphology into: (a) typical CLL, (b) LPL in leukemic phase (>15% of
cells showing lymphoplasmacytic differentiation), (c) SMZL with
(>10%) or without villous lymphocytes, (d) CLL/prolymphocytic leuke-
mia (prolymphocytic cells 1,154%), and (e) heterogeneous forms (poly-
morphic forms).
Immunophenotype analysis of leukemic cells
The specimens were analyzed by means of a ﬂow cytometer using a
panel of monoclonal antibodies deﬁned by each single institution but
always including CD19, CD3, CD5, CD10, FMC7, and CD79b/CD22.
All of the cases had an RMH score of <4. B clonal lymphocytosis was
diagnosed when the surface immunoglobulin k/k ratio was more than 5
for k and less than 0.2 for k light-chains. CD5 expression was consid-
ered negative when the number of cells showing coexpression after
dual CD5/CD19 labeling was less than 10% of the number of cells
expressing CD19. Secondary phenotype markers (CD23, CD11c,
CD49c, CD1c, CD103, CD25, and CD49d) were analyzed in many
specimens. The results are not included here because of the different
techniques used by the different laboratories.
Cytogenetic analysis
The karyotypes were analyzed by means of QFD binding as previ-
ously described [20], and the chromosomes were classiﬁed according
to the International System for Human Cytogenetic Nomenclature [21].
A clone was deﬁned as two cells having the same structural rearrange-
ment, or a gain of the same chromosome, or three cells with the loss
of the same chromosome.
Statistical methods
Descriptive statistics were calculated for the quantitative (mean,
standard deviation, minimum, maximum, and median in the case of
asymmetric distributions) and qualitative variables (absolute and rela-
tive frequencies), together with their pertinent 95% conﬁdence intervals.
The diagnostic classes were compared using Kruskal–Wallis nonpara-
metric analysis of variance for quantitative variables, and the v2 test or
exact Fisher’s test for qualitative variables. The signiﬁcance level of the
multiple comparisons was corrected using Bonferroni’s procedure [22].
OS was deﬁned as the time between the date of diagnosis and the
date of death due to any cause, or the date of the last clinical examina-
tion. TFTT was deﬁned in the group of patients in the ‘‘watch and wait’’
group as the time between the date of diagnosis and the date therapy
was started, or date of the last clinical examination. TTP was deﬁned
in the group of patients treated from the beginning as the time between
the date of diagnosis and the date of relapse/progression, or the date
of the last clinical examination. The cumulative probability of failures of
in the ‘‘watch and wait’’ group (TFTT), progression (TTP), and survival
(OS) was evaluated according to Kaplan and Meier [23], with the differ-
ences between the survival curves being assessed using the log-rank
test [24].
For the Cox proportional hazards regression analysis [25], we used
the covariates with P values of <0.1 in the univariate analysis; the best
subset of prognostic factors was obtained from the full-model using
Wald tests to identify covariates that might be deleted from the model,
and the partial likelihood ratio test to identify the nonsigniﬁcance of the
deleted covariate [26]. The proportional hazard assumption was tested
using the method of Grambsch-Therneau [27]. Cox-Snell [28] residuals
were used to assess the ﬁt of a model based on the Cox proportional
hazard assumption. Goodness of ﬁt was checked by means of the
Hosmer–Lemeshow test [29], and the presence of outliers by means of
deviance residuals versus linear predictor. The stability of the model
was veriﬁed using the bootstrap technique [30].
All of the P values were computed from two-sided tests, and those
that were <0.05 were considered statistically signiﬁcant. All of the data
were analyzed using Stata 8/SE statistical packages [31].
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